Evidence map›Paper›PMID 36686825›Full record

ArticleFrontiers in oncology2022

Quantitative analysis of superb microvascular imaging for monitoring tumor response to chemoradiotherapy in locally advanced cervical cancer.

Yi Zhu, Yixin Tang, Guonan Zhang, Jie Zhang, Yanjie Li, Zhuolin Jiang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yi ZhuOutpatient Department (Ultrasound), The Affiliated Cancer Hospital, University of Electronic Science and Technology of China, Sichuan Cancer Hospital and Institute, Chengdu, China.
Yixin TangOutpatient Department (Ultrasound), The Affiliated Cancer Hospital, University of Electronic Science and Technology of China, Sichuan Cancer Hospital and Institute, Chengdu, China.
Guonan ZhangDepartment Gynecological Oncology, The Affiliated Cancer Hospital, University of Electronic Science and Technology of China, Sichuan Cancer Hospital and Institute, Chengdu, China.
Jie ZhangDepartment Gynecological Oncology, The Affiliated Cancer Hospital, University of Electronic Science and Technology of China, Sichuan Cancer Hospital and Institute, Chengdu, China.
Yanjie LiOutpatient Department (Ultrasound), The Affiliated Cancer Hospital, University of Electronic Science and Technology of China, Sichuan Cancer Hospital and Institute, Chengdu, China.
Zhuolin JiangOutpatient Department (Ultrasound), The Affiliated Cancer Hospital, University of Electronic Science and Technology of China, Sichuan Cancer Hospital and Institute, Chengdu, China.
University of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: As an ultrasound (US) image processing method, superb microvascular imaging (SMI) extracts and visualizes flow signals from vessels through advanced clutter suppression technology. We investigated the feasibility of SMI in monitoring treatment response in patients with locally advanced cervical cancer (LACC) undergoing chemoradiotherapy (CRT). Methods: Forty-nine patients underwent CRT and received SMI examination at 3 time points: before therapy (baseline), 3 weeks during, and 1 month after CRT. The maximum tumor diameter (Dmax), vascularity index (VI), and their percentage changes (ΔDmax and ΔVI) were calculated. ΔDmax was compared with MRI results as the reference standard. Results: Based on the MRI findings, 44 were classified as complete response (CR) group and 5 as partial response (PR) group. The Dmax and ΔDmax showed decrease in CR and PR groups at 3 weeks during CRT (P< 0.05), but no significant difference between the two groups (P > 0.05). Compared to the baseline, significant decrease in VI and ΔVI were observed at during and after treatment in the two groups (P< 0.05). Moreover, there were significant differences in VI and ΔVI at 3 weeks during CRT between the CR and PR groups (P< 0.05). ΔVI at 3 weeks during CRT showed a better predictive performance for responder prognosis than VI (AUC = 0.964, AUC = 0.950, respectively, P = 0.001), with a cut-off value of 41.6% yielding 100% sensitivity and 86.4% specificity. Conclusions: The SMI parameters (VI and ΔVI) have potential for monitoring treatment response in LACC.

Indexed as

cervical cancerchemoradiotherapysuperb microvascular imagingultrasoundvascularity index

Identifiers

PMID36686825
PMCPMC9848652
OpenAlexW4313585125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.